StockIQStockIQ.tech
Account
Register Login

Danaher Corporation (DHR) Stock Analysis

--

Free AI-powered analysis and research for Danaher Corporation stock

Sector: Healthcare

DHR snapshot

Data as of 9 Oct 2026 close. Updated daily.

Last close
219.81 USD (+1.08%)
52-week range
160.93 – 242.80
Position in range
72%
1-year change
+8.6%
Market cap (USD)
$154.5B
P/E (trailing)
38.8
RSI (14-day)
54
vs 200-day average
+9.1%
MACD
Below signal line
StockIQ score: 61/100 · Positive signals

Danaher Corporation scores 61/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 72% of its 52-week range, up 8.6% over the past year. Latest reported figures show a profit margin of 15.9%, return on equity of 7.6% and revenue growth of +5.5%.

What is driving the score
  • RSI Neutral: +5
  • Strong Uptrend: +12
  • MACD Bearish: -8
  • High P/E (38.8): -10
  • Good Profit Margin (15.9%): +5
  • Above MA200: +4
  • Positive YTD (+8.6%): +3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full DHR report

Danaher Corporation (DHR) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze DHR Now →

📰 Latest Update

Danaher’s Stock Is Pricing in a Recovery. Can Its Earnings Deliver?

Danaher Corporation's stock is currently reflecting optimism about a potential recovery in its earnings, following a period of underperformance. Investors are closely monitoring the company's ability to meet these expectations, as strong earnings could validate the stock's recent gains and signal a turnaround in its business operations. The outcome will be crucial for investor confidence and could influence future stock performance.

Read full article →

History

People also watch

BMY
Bristol-Myers Squibb Company
--
AMGN
Amgen Inc.
--
GILD
Gilead Sciences Inc.
--
INO
Inovio Pharmaceuticals, Inc.
--
RNAC
Cartesian Therapeutics, Inc.
--